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A B S T R A C T
Polymer microparticles are widely used as acellular drug delivery platforms in regenerative medicine, and have
emerging potential as cellular scaﬀolds for therapeutic cell delivery. In the clinic, PLGA microparticles are
typically administered intramuscularly or subcutaneously, with the clinician and clinical application site de-
termining the precise needle gauge used for delivery. Here, we explored the role of needle diameter in micro-
particle delivery yield, and develop a modiﬁed viscosity formulation to improve microparticle delivery across a
range of clinically relevant needle diameters. We have identiﬁed an optimal biocompatible formulation con-
taining 0.25% pluronic F127 and 0.25% carboxymethyl cellulose, which can increase delivery payload to 520%
across needle gauges 21–30G, and note that needle diameter impacts delivery eﬃcacy. We use this formulation
to increase the delivery yield of PLGA microparticles, and separately, PLGA-cell scaﬀolds supporting viable
mesenchymal stem cells (MSCs), demonstrating the ﬁrst in vitro delivery of this cell scaﬀold system. Together,
these results highlight an optimal formulation for the delivery of microparticle and microparticle-cell scaﬀolds,
and illustrate how careful choice of delivery formulation and needle size can dramatically impact delivery
payload.
1. Introduction
Poly (DL-lactic acid-co-glycolic acid) (PLGA) materials are widely
used therapeutics with applications in drug delivery (Rao et al., 2010;
Rafati et al., 2012; Simon-Yarza et al., 2013), tissue engineering (Park
et al., 2016), and cellular scaﬀolding (Lee et al., 2015; Qutachi et al.,
2014). In drug delivery applications, PLGA microparticles oﬀer tunable,
biodegradable kinetic release proﬁles. They are FDA approved for a
variety of applications, and can often be administered via localised or
systemic injection (Rafati et al., 2012; Cappellano et al., 2014; Park
et al., 2014). Larger 3-dimensional PLGA structures have also been
surgically implanted as cellular scaﬀolds for regenerative medicine
(Hernandez et al., 2010; Kochenderfer et al., 2010), however there are
limited examples of systems combining the extracellular support matrix
provided by PLGA (Lee et al., 2015; Han et al., 2015) with the tunable
kinetic release of soluble factors (Cappellano et al., 2014). Through this
combination of a physical support matrix and soluble cellular cues,
microparticle cell scaﬀold systems with controlled release properties
are able to support and direct transplanted cell behaviour.
A current challenge in the delivery of microparticles, cells, or mi-
croparticle-cell combination therapies lies in maintaining an eﬀective
therapeutic dose across varied application routes. In many systems, a
common clinical administration route is the localised injection of ma-
terials using either pre-ﬁlled or self-ﬁlled syringes together with a
needle (Garbayo et al., 2016; McHugh et al., 2015; Fu et al., 2016; Kim
et al., 2016). Selection of an appropriate needle gauge depends on the
therapeutic application; ﬁner needles of 29G are often used for spatially
accurate delivery of materials to the spinal cord, compared to 14G
needles frequently used for intramuscular injection (Dittmann et al.,
1993; Mavrogenis et al., 2015; Songur et al., 2011; Sivera et al., 2008;
Raftesath and Fitzgerald, 2014). In cell-only systems, recent studies
have suggested that injection parameters (including needle gauge, ﬂow
rate and applied force) can aﬀect both the number of cells delivered and
the ability of these cells to undergo phenotypic diﬀerentiation (Mamidi
et al., 2012; Amer et al., 2016; Amer et al., 2015a,b), however these
studies have yet to be applied to delivery of acellular microparticle
systems.
Maintaining an eﬀective therapeutic dose across a broad range of
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administration routes remains an ongoing consideration for the clinical
application of drug delivery systems (Cilurzo et al., 2011; Kearney and
Mooney, 2013). To our knowledge, there has yet to be a study on the
eﬀect of injection parameters on delivery of either PLGA microparticles
alone, or PLGA microparticles in conjunction with cells. Here, we ex-
plore modiﬁed viscosity systems to enhance both microparticle delivery
and microparticle-cell scaﬀold delivery across a range of clinically re-
levant needle gauges. First, we explore PLGA particle delivery across a
range of needle gauges with controlled plunger force. Next, we in-
vestigate modiﬁed delivery formulations using the thickening agent
carboxymethylcellulose (CMC) (Nakanishi, 1966) and the amphiphilic
polymer pluronic F127 (Prameela et al., 2015), probing their ability to
modify viscosity and their eﬀect on particle delivery across needle sizes.
Finally, we investigate the eﬀect of our lead formulation on the viability
of human MSCs, and demonstrate the use of our formulation in deli-
vering multifunctional PLGA microparticle scaﬀolds with human MSCs
in vitro.
2. Materials and methods
2.1. Fabrication of PLGA microparticles
Non-porous PLGA particles were fabricated using 20% PLGA (50:50,
52 kDa Lakeshore Biomaterials) in dichloromethane (DCM) (Fischer) by
either a single or double emulsion method. In the single emulsion
method, the polymer solution was homogenised in 250mL of 0.3%
polyvinyl alcohol (13–24 kDa, Sigma-Aldrich) using a high speed
Silverson L5M homogeniser. The resulting emulsion was left stirring at
300 RPM until particles hardened. In the double emulsion method,
100 µL of an aqueous solution containing 10mg Amoxicillin (Abcam)
was homogenised in the polymer solution. The resultant primary water
in oil (w/o) emulsion was then homogenised again in the 0.3% PVA and
the resultant water in oil in water (w/o/w) double emulsion was left
stirring until particles hardened. Particles were extracted by cen-
trifugation, washed, and lyophilised before being stored at−20 °C until
use. Porous PLGA particles were produced using a double emulsion
method as previously described (Qutachi et al., 2014). Brieﬂy, 20% (w/
v) PLGA in dichloromethane was treated with phosphate buﬀered saline
(PBS, Gibco) as a porogen. Post fabrication, the particles were treated
with ethanolic sodium hydroxide (sodium hydroxide (Sigma-Aldrich)
and absolute ethanol (Fischer)) to enhance surface porosity. The par-
ticles were then extracted by centrifugation, washed, and lyophilised
before being stored at −20 °C until use.
Particles were characterised using scanning electron microscopy
and laser diﬀraction. Brieﬂy, particles were loaded onto carbon disks on
aluminium stubs (Agar Scientiﬁc), sputter coated with gold (Balzers
Union Ltd.) and imaged on an JEOL 6060L system. The mean diameter
and particle size distribution were analysed using a Coulter LS230
particle size analyser (Beckman, UK). Particle size distribution was then
determined as a function of the particle diﬀraction and plotted as a
function of volume percentage.
2.2. Delivery formulations
Particles were resuspended at 5mg/mL in DMEM (Gibco), con-
taining between 0 and 10% pluronic F127 (Sigma-Aldrich) or 0–10%
medium viscosity sodium carboxymethylcellulose (CMC) (Sigma-
Aldrich). Combined formulations containing between 0 and 0.5%
pluronic and 0–0.5% CMC were also prepared. Formulation solutions
were kept at 4 °C until use. Solution viscosity was measured using a
rheometer with cone and plate geometry at 0.1° angle (Anton Parr-
Physica MCR 301)), using a shear ramp from 0 to 100 1/s at 25 °C.
2.3. Particle injection
PLGA microparticles (5.0 mg) were suspended in polymer/media
formulation (1.0 mL) in 1.5 mL Eppendorf tubes under repeated pipet-
ting and vortexing. The total volume was drawn up into a 1mL dis-
posable syringe (BD) and a needle (gauges 21G, 23G, 25G, 27G, 30G
(BD Microlance)) ﬁtted to the syringe prior to ejection of the total vo-
lume into a new Eppendorf tube. A sample (10 µL) was taken from the
ejected volume and particles were counted using a haemocytometer.
For comparison, particles were also ejected through needles without a
syringe to provide a control. Injections were considered to have failed
when the contents of the syringe could not be ejected using a me-
chanically controlled syringe pump. This is usually due to a blockage in
the needle or aggregation of the suspension at the syringe tip, resulting
in the syringe contents not being completely emptied. Injection failures
are recorded and measured in counts, and the calculated values illus-
trates the percentage of “failed” injections per condition.
2.4. Injection forces and calculated shear rates
For each needle-syringe combination, the initial and glide force
were determined using a texture analyser (TA.HD plus, Stable micro
systems). 1mL of formulation was loaded into a 1mL syringe (BD), and
ﬁtted with an appropriate needle into the injection rig. A 10mm cy-
linder probe was lowered into contact with the plunger, with no pre-test
force, before a 1mm/s ejection rate was applied in compression mode.
The initial force was calculated as the force required to overcome the
resistance to movement of the plunger, whereas the glide force was
calculated as the average force required to evacuate the syringe at
1mm/s. For formulations tested with microparticles, a concentration of
5mg/mL particles suspended in 1mL solution was used. Shear rates
were calculated using Poiseuilles equation;
=γ Q
πr
4
3
where γ is shear rate in s−1, Q is ﬂow rate in cm3/s, and r is needle
radius in cm. Shear rates were calculated using both experimental ﬂow
rate (for 1mm/s plunger ejection) and theoretical ﬂow rates 1mL/h
and 20mL/h expected to be used in clinic, described in Table 2.
2.5. PLGA microparticle release studies
In vitro testing of the controlled release of Amoxicillin encapsulated
within PLGA microparticles was performed using Transwell inserts
(Corning, UK). 25mg of PLGA microparticles were suspended in 1.5mL
of the described formulations, and incubated at 37 °C. The concentra-
tion of Amoxicillin in release medium was quantiﬁed by UV detection at
300 nm using a plate reader (Tecan) with concentration determined
from a calibration curve.
2.6. Cell viability
Human bone marrow derived mesenchymal stem cells (MSCs)
(UE6E7T-11 cells sourced from the Japanese Stem Cell Bank) were used
for all cellular assays. The Prestoblue cell viability assay (Invitrogen
Life Sciences, UK) was performed 1 and 24 h post-seeding (n= 6). Each
sample was submerged in 1mL of 10% Prestoblue (Invitrogen Life
Sciences, UK) in media; all samples were incubated at 37 °C for 30min.
Triplicate 100 µL media samples from each well were read on a Tecan
plate reader with the excitation wavelength set to 535 nm and the
emission wavelength set at 615 nm.
2.7. Injection of cells cultured on particles
Porous particles were treated with Tween and then antibiotic/an-
timycotic solution (Sigma-Aldrich). Commercially available human
mesenchymal stem cells (MSCs) (Japanese Stem Cell Bank) were seeded
at 200,000 per well in 12-well plates, with 8mg PLGA particles added
per well, and incubated overnight at 37 °C in DMEM medium
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supplemented with 10% foetal calf serum, 1% antibiotic/antimycotic
solution, 1% L-glutamine (2mM) and 1% non-essential amino acids
(Sigma-Aldrich). Wells were centrifuged, and the cell pellet re-sus-
pended in DMEM or formulation conditions. As described previously,
this suspension was injected into a fresh 12-well plate, and incubated
for 10min with 10% Presto blue at 37 °C. Cell number per well was
quantiﬁed using a Tecan plate reader. Samples were formalin ﬁxed for
20min at room temperature, washed with PBS multiple times and then
imaged by SEM.
2.8. Delivery eﬃcacy
Delivery eﬃcacy was calculated by comparing the number of par-
ticles delivered using a speciﬁc formulation and needle combination to
the number of particles delivered in a basal media solution. Particles
were counted using a hemocytometer. For example, to compare the
delivery eﬃcacy of particles suspended in basal media through needle-
free syringes and 27G needles, a suspension of PLGA particles was
loaded into at least six identical syringes, three of which were uncapped
and three capped with 27G needles. Syringes were loaded onto the
controlled rate syringe pump, and ejected at constant plunger speed of
1mm/s. An aliquot of the ejected solution was transferred to a hemo-
cytometer and the number of ejected particles counted. To calculate
delivery eﬃcacy, we averaged the number of particles for each condi-
tion and calculated eﬃcacy as follows;
=
×
delivery efficacy average number of particles delivered in condition X
average number of particles delivered in basal media
100
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 7)
software. ANOVA analysis was used for all statistical testing, performed
on data from between 3 and 6 repeat experiments. Analysis is con-
sidered signiﬁcant, and the ∗ designation is assigned, if p > 0.05∗,
p > 0.01∗∗, p > 0.001∗∗∗, p > 0.0001∗∗∗∗. Bar graphs represent the
mean of 3–6 individual repeats, with associated error bars to show the
standard error in the mean (SEM). Details of individual statistical tests
(ie. one way or two way ANOVA, number of repeats) are provided in
the ﬁgure caption for each graph.
3. Results and discussion
3.1. The eﬀect of needle gauge on microparticle delivery
We fabricated PLGA microparticles of 27 µm diameter as described
in Section 2.1 (Fig. 1A), and investigated delivery eﬃcacy through
needles between 21 and 30G, corresponding to internal needle dia-
meters currently used in clinic ranging from over 500 µm to around
160 µm (Table 1). Using a syringe pump set up with constant ﬂow rate
of 1mm/s, we evaluated the ejection of PLGA microparticles suspended
in basal media solution through a range of needle gauges (Fig. 1B). All
needle gauges tested were able to deliver the microparticles, however
we ﬁnd that narrower needle gauges of 27G and 30G failed to deliver
microparticle solutions as eﬀectively as either needle free or large-bore
needle systems, with delivery eﬃcacy reduced to 61% in 27G needles
compared to needle free systems. Given the internal needle diameters of
27G and 30G needles (210 µm and 160 µm respectively) are wider than
the 26.9 µm (± SD 11.2 µm) diameter of the microparticles (Fig. 1A),
this suggests that the particle delivery through narrow gauge needles is
aﬀected not only by particle size, but also the dynamics of the ﬂuid
ejection from the syringe. To explore this further, we investigated the
eﬀect of altering the solution viscosity, and so ejection ﬂuid dynamics,
of the delivery formulation in needle delivery systems.
3.2. PLGA microparticle delivery using modiﬁed formulations
Formulations containing the thickening agent carbox-
ymethylcellulose (CMC) (Fig. 1C), pluronic F127 (Fig. 1D) to modulate
wettability, and CMC/pluronic F127 (Fig. 1E) combination formula-
tions were tested for their ability to deliver PLGA microparticles. Fig. 1
demonstrates that increasing concentrations of either CMC or pluronic
F127 in media signiﬁcantly increased particle delivery, illustrated by
the 400% increase of particle delivery in systems using either 5%
pluronic F127 or 2% CMC, compared to un-supplemented media. We
then investigated combination formulations with compositions of be-
tween 0.125 and 0.5% of CMC and pluronic F127 in media. Fig. 1E
illustrates that particle delivery was signiﬁcantly improved in all
combination formulations tested, and broadly increased as the con-
centration of CMC/pluronic F127 in solution increased.
We calculated the shear rate used during our experimental injec-
tions at a constant plunger rate of 1mm/s (Table 2). These values
suggest our experimental injection system experiences low shear be-
tween 150 and 500/s. We examined the eﬀect of formulation compo-
sition on viscosity at comparable shear rates between 1 and 100/s.
Comparing the formulations, Fig. 1F illustrates that the viscosity of
each composition remains broadly constant against increasing shear
between 1 and 100/s. In systems with constant CMC concentration and
varying pluronic F127 concentration, viscosity measurements are si-
milar, whilst viscosity measurements roughly double as the con-
centration of CMC doubles in the formulation, suggesting that viscosity
properties are broadly driven by the CMC concentration in solution
(Voigt et al., 2012; Ahmed et al., 2011). Given that many clinically
administered injections are delivered at higher ﬂow rates than those
tested experimentally (Nguyen et al., 2002; Salman et al., 2017), we
next calculated the expected ﬂow rate and shear rate during more rapid
administration through various needle gauges (Table 2). Needles in-
jecting ﬂow rates of 1mL/h and 20mL/h (ﬂow rates more commonly
used for clinical infusion regimes) experience much higher shear rates
through similar needle gauges.
At the shear rates tested here, supplementing basal media with
pluronic acid and CMC can increase microparticle delivery. There are
several potential explanations for this, including the changes in solution
viscosity and the increased wetting of microparticles in these for-
mulations. The increased solution viscosity may help to form a stable
microparticle suspension during syringe evacuation, which prevents
particles being forced to the side of the syringe. Particles at the side of
syringe can be statically attracted to the syringe casing and are less
likely to be ejected (Whitaker et al., 2011). Additionally, Fig. 1E in-
dicates that increasing the total polymer concentration to above 0.5%,
can increase delivery payload. It is likely that the negatively charged
polymers help to combat static and attractive charges between the
particles and the syringe, facilitating particle ejection (Park et al., 2014;
Voigt et al., 2012). The combined eﬀects of increased polymer con-
centration, particle wetting and increased viscosity, are likely re-
sponsible for the increase in delivery.
3.3. Modiﬁed delivery formulations using clinical needle gauges
All combination formulations tested demonstrated enhanced mi-
croparticle delivery compared to a basal media control in a 23G needle
system. We then explored whether these combination formulations
were able to enhance microparticle delivery across a range of clinically
relevant needle gauges (Dittmann et al., 1993; Mavrogenis et al., 2015;
Songur et al., 2011; Raftesath and Fitzgerald, 2014; Gill and Prausnitz,
2007; Fateh et al., 2014). Fig. 2A compares the number of micro-
particles delivered for each formulation in 21–27G needles, and Fig. 2B
summarises the average delivery across all needle gauges tested. There
is a signiﬁcant increase in particle delivery across all needle gauges
using CMC and pluronic F127 formulations in comparison to basal
media (p < 0.001 in all formulations, and all needle gauges, Turkey’s
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multiple comparison tests and two-way ANOVA), with delivery in-
creasing on average between 300 and 400% compared to particles
delivered in basal media in the same needle gauge.
We further explored needle blockage and injection failure for each
of these formulations (Fig. 2C) in needle gauges. Fig. 2C demonstrates
that the 0.25% pluronic F127 and 0.25% CMC formulation had no in-
jection failures compared to other formulations which occasionally
resulted in a blocked needle injection failure. Considering this 0.25%
pluronic F127 and 0.25% CMC formulation in more detail, we ﬁnd that
microparticle delivery is signiﬁcantly increased in all needle gauges
tested using this formulation compared to a basal media control
(Fig. 2D), with increases in delivery between 320 and 750% compared
to basal media (Table 3), and an average increase in microparticle
delivery of 520% across all needle gauges. This formulation is therefore
broadly applicable to a range of clinical needle gauges.
3.4. Modiﬁed viscosity formulations for the delivery of drug loaded
microparticles
We investigated the applicability of the lead 0.25% CMC 0.25%
pluronic F127 formulation for the delivery of drug-eluting micro-
particles and microparticle-cell scaﬀold therapeutics. First, the release
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Fig. 1. Properties of pluronic F127 and CMC modiﬁed solutions. (A) Size distribution of PLGA microparticles used in this study, measured by laser diﬀraction. (B)
PLGA microparticle delivery from a stock of 5mg/mL through syringes ﬁtted with various needle gauges (C–E) Increasing concentrations of pluronic F127 (C) CMC
(D) and pluronic F127/CMC combination formulations (E) were tested for their ability to deliver microparticles from a stock solution through 27G needles (F)
Viscosity measurements at increasing shear rate, measured for combination formulations at 25 °C. All statistical tests show one way ANOVA where p > 0.05*,
p > 0.01**, p > 0.001***, p > 0.0001****, bars represent mean of 3–6 repeats with SEM error bars.
Table 1
Clinical needle gauges and needle bore internal diameters.
Needle Gauge Needle bore diameter
(mm)
Needle Gauge Needle bore diameter
(mm)
15 1.372 25 0.260
16 1.194 26 0.260
17 1.067 27 0.210
18 0.838 28 0.184
19 0.686 29 0.184
20 0.603 30 0.159
21 0.514 31 0.133
22 0.413 32 0.108
23 0.337 33 0.108
24 0.311 34 0.0826
Table 2
Calculated shear rate through clinical needle gauges at varying ﬂow. Shear rate
was calculated using Poiseuilles equation for needle gauges between 21 and
30G, using experimental ﬂow rates tested using 1mm/s plunger speed, and
theoretical ﬂow rates of 1 or 20mL/h, all values rounded to 3 signiﬁcant ﬁg-
ures.
Needle
gauge
Needle
diameter
(cm)
Experimental ﬂow
(plunger at 1mm/s)
Theoretical
ﬂow (1mL/h)
Theoretical
ﬂow (20mL/
h)
Q (cm3/s) Shear
rate
(s−1)
Shear rate
(s−1)
Shear rate
(s−1)
30G 0.159 1.98E−07 503 704,000 14,100,000
27G 0.210 3.46E−07 380 306,000 6,110,000
25G 0.260 5.31E−07 308 161,000 3,220,000
23G 0.337 8.92E−07 237 74,000 1,480,000
21G 0.514 2.07E−06 156 20,800 417,000
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proﬁle of amoxicillin from amoxicillin loaded PLGA microparticles was
tested, exploring microparticles delivered through a 27G needle with
and without the modiﬁed viscosity formulation (Fig. 3A). As expected,
the total amount of amoxicillin released was increased when our de-
livery formulation was used. As the kinetics of release remained broadly
unaﬀected, we suggest that this is due to the increased delivery yield
using the 0.25% CMC 0.25% pluronic F127 formulation.
Interestingly, the addition of pluronic acid and CMC may also alter
microparticle surface wetting and shear forces experienced during
ejection, which could also inﬂuence drug release kinetics. The hydro-
philicity of PLGA surfaces aﬀects polymer degradation kinetics, and is
correlated with both co-polymer composition and liquid solvent po-
larity (Chen et al., 2017; Vargha-Butler et al., 2001). The addition of
CMC and pluronic acid to the basal media formulation may alter the
polarity of the liquid phase, and could directly impact microparticle
surface wetting and so drug release kinetics. Formulations containing
CMC and pluronic acid have also been shown to alter shear forces ex-
perienced by cells during stirred culture (Gallardo Rodriguez et al.,
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Fig. 2. Modiﬁed solutions across needle gauges. Increasing concentrations of (A) pluronic F127/CMC combination formulations were tested for their ability to deliver
microparticles from a stock solution across a range of needle gauges. (B) Average delivery of microparticles across all needle gauges (21–27G) in diﬀerent com-
bination formulations. (C) Number of needle blockages in each formulation, n=10 for each formulation. Needles 30G, 27G, 25G, 23G and 21G were tested, with
blockages found in 25–30G. (D) A comparison between basal media and 0.25% pluronic 0.25% CMC for the delivery of microparticles across needle gauges 21G–27G.
All statistical tests show two way ANOVA where p > 0.05*, p > 0.01**, p > 0.001***, p > 0.0001****, bars represent mean of 3–6 repeats with SEM error bars.
Table 3
Delivery eﬃcacy Delivery eﬃcacy was calculated by comparing the number of particles delivered. For example, PLGA microparticles were suspended in either basal
media, or media supplemented with 0.25% CMC and 0.25% Pluronic F127, loaded into a standard syringe ﬁtted with the appropriate gauge needle. Syringes were
loaded onto the mechanically controlled syringe pump, and ejected. An aliquot of the ejected solution was transferred to a hemocytometer and the number of ejected
particles counted. At least three syringe ejections were tested for each condition, and delivery eﬃcacy calculated by comparing to the number of particles ejected in
the basal media formulation.
Needle system and media
composition
Average number of particles
delivered/mL
Compare to: Needle system and media
composition
Average number of particles
delivered/mL
Calculated delivery eﬃcacy
(%)
Needle free, basal media 0.90×106 Needle free, 0.25% CMC 0.25%
pluronic F127
4.95× 106 550%
21G, basal media 0.94×106 21G, 0.25% CMC 0.25% pluronic F127 5.06× 106 538%
23G, basal media 1.17×106 23G, 0.25% CMC 0.25% pluronic F127 4.96× 106 424%
25G, basal media 1.29×106 25G, 0.25% CMC 0.25% pluronic F127 4.08× 106 316%
27G, basal media 0.55×106 27G, 0.25% CMC 0.25% pluronic F127 2.91× 106 529%
30G, basal media 0.58×106 30G, 0.25% CMC 0.25% pluronic F127 4.37× 106 753%
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2011; Xu et al., 1995). The addition of these molecules to the for-
mulation may therefore impact the shear forces particles are exposed to
during ejection. To explore the relative importance of particle delivery
yield, surface wetting, and ejection shear in controlling drug delivery,
further studies should be performed to independently isolate these
variables.
3.5. Modiﬁed viscosity formulations for the delivery of microparticles-cell
scaﬀolds
Next, we investigated the eﬀect of our modiﬁed viscosity formula-
tion on cell viability. At low concentrations, both CMC and pluronic
acid moieties have been shown to protect cells from detrimental eﬀects
due to excessive shear forces (Gallardo Rodriguez et al., 2011; Xu et al.,
1995). We examined the viability of human mesenchymal stem cells
(MSCs) at 1 h and 24 h in media supplemented with our formulation.
Fig. 3B shows cell proliferation calibrated using the Presto Blue meta-
bolic assay in both conditions. In both solutions, cells demonstrate a
similar viability at 1 h, and at 24 h show a signiﬁcant increase in
metabolic activity compared to 1 h. Cells remained viable in the for-
mulation for up to 24 h, though there was a reduction in metabolic
activity after incubation for 24 h in our formulation compared to basal
media. At the 1 h timepoint, which represents a realistic timeframe for
the clinical administration of cell-particle systems, there was no sig-
niﬁcant diﬀerence in viability between cells cultured in basal media
and the 0.25% pluronic F127 0.25% CMC formulation, indicating this
formulation may be suitable for the in vivo delivery of microparticle-cell
systems.
Finally, we investigated the delivery of cells together with PLGA
microparticles through syringes, either with or without a 27G needle, in
basal media or our 0.25% CMC and 0.25% pluronic F127 formulation.
Fig. 3C shows SEM images of cells delivered together with PLGA mi-
croparticle scaﬀolds, and demonstrates the integrity of both the parti-
cles and the cells post injection, and that the PLGA particles can be used
to provide a scaﬀold for the cells. Fig. 3D illustrates that in both needle
free and 27G needle delivery systems, the use of the 0.25% CMC and
0.25% pluronic F127 formulation signiﬁcantly increased cell delivery
by 200–400% compared to basal media. These results are comparable
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Fig. 3. Eﬀect of modiﬁed formulations on drug release and cell behaviour (A) Cumulative amoxicillin release was analysed from PLGA microparticles delivery using
syringes ﬁtted 27G needles. PLGA microparticles were suspended in basal media or 0.25% pluronic 0.25% CMC supplemented media (C) SEM image of microparticle
cell scaﬀold post-delivery through a 27G needle. Scale bar 10 µm. (B, D) Cell number after cellular incubation in basal media, or media supplemented with 0.25%
CMC and 0.25% pluronic F127 after 1 and 24 h compared to an initial seeding density (B), (D) Cell number post simulated delivery through a needle free of 27G
needle system using basal media or media supplemented with 0.25% CMC and 0.25% pluronic F127. Statistical analysis performed using ANOVA, all statistical tests
show p > 0.05*, p > 0.01**, p > 0.001***, p > 0.0001****, bars represent mean of 3–6 repeats with SEM error bars.
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to our earlier studies demonstrating enhanced delivery in microparticle
only systems, and support our conclusion that basal media supple-
mented with 0.25% CMC and 0.25% pluronic F127 provides a for-
mulation that can enhance delivery of PLGA microparticles, and mi-
croparticle-cell combination therapeutics, in needle delivery systems
without compromising cell viability. We believe these results show the
ﬁrst needle delivery of a porous PLGA microparticle-MSC system, as
proof-of-concept drug-eluting microparticle-cell scaﬀolds capable of
combining a biodegradable cell support with localised drug delivery.
Encapsulating soluble factors which direct host- or transplanted cell
behaviour within these microparticle scaﬀolds would increase their
versatility and make them a powerful tool for cell transplant.
4. Conclusion
The delivery of a controlled dose of microparticles is crucial for
therapeutic applications. We ﬁnd that the addition of viscosity modi-
ﬁers can enhance particle delivery up to 520% across needle gauges
between 21 and 30G, and identify a formulation of basal media sup-
plemented with 0.25% pluronic F127 and 0.25% CMC as providing an
optimal system. Although the polymers explored here increase delivery
across all needle sizes tested, our results indicate that selection of an
appropriate needle is also an important parameter to consider. We
tested the biocompatibility of our lead formulation, ﬁnding that cells
remain viable in the formulation for up to 24 h, and demonstrate that
this formulation is suitable for the improved in vitro delivery of drug
eluting PLGA microparticles, and microparticle-cell scaﬀolds. These
microparticle-cell scaﬀolds oﬀer the potential to simultaneously sup-
port cells for transplant and modulate the host environment/trans-
planted cell behaviour through the controlled release of pharmaceu-
ticals. Together, these results pave the way for further exploration of
microparticle-cell scaﬀold and delivery systems for in vivo cell trans-
plantation. Additionally, these results have important implications for
the application of microparticle and microparticle-cell therapeutics,
and may also apply to other polymer based pharmaceuticals or protein
biologics delivered by needle. In many cases, in vitro testing and clinical
applications use diﬀerent delivery strategies, with diﬀerent needle and
formulation systems, which could lead to diﬀerences in administered
therapeutic dose. In order to match in vitro, pre-clinical and therapeutic
outcomes, administration parameters (such as needle diameter and
delivery formulation) should be carefully considered, and ideally con-
served between pre-clinical and therapeutic applications.
Acknowledgements
We would like to acknowledge funding provided by the UKRMP
Acellular Hub and the EPSRC E-TERM program, which helped to sup-
port this work.
References
Ahmed, T.A., et al., 2011. In vitro release, rheological, and stability studies of mefenamic
acid coprecipitates in topical formulations. Pharm. Dev. Technol. 16 (5), 497–510.
Amer, M.H., et al., 2015b. Evaluation of delivery of mesenchymal stem cells using small-
gauge needles: tailoring administration of cell-based therapies for eﬃcient clinical
translation. Tissue Eng. Part A 21, S265.
Amer, M.H., et al., 2016. A detailed assessment of varying ejection rate on delivery ef-
ﬁciency of mesenchymal stem cells using narrow-bore needles. Stem Cells Transl.
Med. 5 (3), 366–378.
Amer, M.H., White, L.J., Shakesheﬀ, K.M., 2015a. The eﬀect of injection using narrow-
bore needles on mammalian cells: administration and formulation considerations for
cell therapies. J. Pharm. Pharmacol. 67 (5), 640–650.
Cappellano, G., et al., 2014. Subcutaneous inverse vaccination with PLGA particles loaded
with a MOG peptide and IL-10 decreases the severity of experimental autoimmune
encephalomyelitis. Vaccine 32 (43), 5681–5689.
Chen, W.L., et al., 2017. Eﬀect of particle size on drug loading and release kinetics of
geﬁtinib-loaded PLGA microspheres. Mol. Pharm. 14 (2), 459–467.
Cilurzo, F., et al., 2011. Injectability evaluation: an open issue. AAPS PharmSciTech 12
(2), 604–609.
Dittmann, M., et al., 1993. 9 Years of clinical-experience with 29 gauge spinal needles. Br.
J. Anaesthesia 70, 65.
Fateh, M., et al., 2014. Syringe-type and needle gauge have no role in adverse events
following DTwP immunization: a randomized multicenter trial. Pediatric Infect. Dis.
J. 33 (9), E239–E246.
Fu, J., et al., 2016. Subconjunctival delivery of dorzolamide-loaded poly(ether-anhy-
dride) microparticles produces sustained lowering of intraocular pressure in rabbits.
Mol. Pharm. 13 (9), 2987–2995.
Gallardo Rodriguez, J.J., et al., 2011. Carboxymethyl cellulose and Pluronic F68 protect
the dinoﬂagellate Protoceratium reticulatum against shear-associated damage.
Bioprocess Biosyst. Eng. 34 (1), 3–12.
Garbayo, E., et al., 2016. Catheter-based intramyocardial injection of FGF1 or NRG1-
loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion.
Sci. Rep. 6.
Gill, H.S., Prausnitz, M.R., 2007. Does needle size matter? J. Diabetes Sci. Technol. 1 (5),
725–729.
Han, K.-S., et al., 2015. Eﬀect of demineralized bone particle/poly(lactic-co-glycolic acid)
scaﬀolds on the attachment and proliferation of mesenchymal stem cells. J. Biomater.
Sci. Polym. Ed. 26 (2), 92–110.
Hernandez, R.M., et al., 2010. Microcapsules and microcarriers for in situ cell delivery.
Adv. Drug Deliv. Rev. 62 (7–8), 711–730.
Kearney, C.J., Mooney, D.J., 2013. Macroscale delivery systems for molecular and cellular
payloads. Nat. Mater. 12 (11), 1004–1017.
Kim, Y.-C., et al., 2016. Transplantation of mesenchymal stem cells for acute spinal cord
injury in rats: comparative study between intralesional injection and scaﬀold based
transplantation. J. Korean Med. Sci. 31 (9), 1373–1382.
Kochenderfer, J.N., et al., 2010. A phase I clinical trial of treatment of B cell malignancies
with autologous anti CD19 CAR transduced T cells. Blood 116 (21), 1179–1180.
Lee, Y.S., et al., 2015. Development of porous PLGA/PEI1.8k biodegradable microspheres
for the delivery of mesenchymal stem cells (MSCs). J. Controll. Release 205,
128–133.
Mamidi, M.K., et al., 2012. Impact of passing mesenchymal stem cells through smaller
bore size needles for subsequent use in patients for clinical or cosmetic indications. J.
Transl. Med. 10, 229.
Mavrogenis, G., et al., 2015. 25-gauge histology needle versus 22-gauge cytology needle
in endoscopic ultrasonography-guided sampling of pancreatic lesions and lympha-
denopathy. Endosc. Int. Open 3 (1), E63–E68.
McHugh, K.J., et al., 2015. Single-injection vaccines: progress, challenges, and opportu-
nities. J. Controll. Release 219, 596–609.
Nakanishi, Y., 1966. Studies on pharmaceutical suspensions. 3. Viscosities of the dis-
persed systems of barium sulfate in MC and CMC aqueous solutions. Yakugaku Zasshi
86 (11), 997–1000.
Nguyen, N.T., Huang, X.Y., Chuan, T.K., 2002. MEMS-micropumps: a review. J. Fluids
Eng. Trans. ASME 124 (2), 384–392.
Park, C.H., et al., 2014. Needle-free transdermal delivery using PLGA nanoparticles: Eﬀect
of particle size, injection pressure and syringe oriﬁce diameter. Colloids Surf. B:
Biointerfaces 123, 710–715.
Park, J.S., et al., 2016. Stem cell diﬀerentiation-related protein-loaded PLGA micro-
spheres as a novel platform micro-typed scaﬀold for chondrogenesis. Biomed. Mater.
11 (5).
Prameela, G.K., et al., 2015. Physicochemical perspectives (aggregation, structure and
dynamics) of interaction between pluronic (L31) and surfactant (SDS). Phys. Chem.
Chem. Phys. 17 (45), 30560–30569.
Qutachi, O., et al., 2014. Injectable and porous PLGA microspheres that form highly
porous scaﬀolds at body temperature. Acta Biomater. 10 (12), 5090–5098.
Rafati, A., et al., 2012. Chemical and spatial analysis of protein loaded PLGA micro-
spheres for drug delivery applications. J. Controll. Release 162 (2), 321–329.
Raftesath, D., Fitzgerald, M., 2014. Inﬂuence of needle gauge used for venipuncture on
automated platelet count and coagulation proﬁle in dogs. Aust. Vet. J. 92 (3), N16.
Rao, D.A., et al., 2010. Biodegradable PLGA based nanoparticles for sustained regional
lymphatic drug delivery. J. Pharm. Sci. 99 (4), 2018–2031.
Salman, D., et al., 2017. Evaluation of the performance of elastomeric pumps in practice:
are we under-delivering on chemotherapy treatments? Curr. Med. Res. Opin. 33 (12),
2153–2159.
Simon-Yarza, T., et al., 2013. PEGylated-PLGA microparticles containing VEGF for long
term drug delivery. Int. J. Pharm. 440 (1), 13–18.
Sivera, F., Aragon, R., Pascual, E., 2008. First metatarsophalangeal joint aspiration using
a 29-gauge needle. Ann. Rheumatic Dis. 67 (2), 273–275.
Songur, N., et al., 2011. Comparison of 19-and 22-gauge needles in EUS-guided ﬁne
needle aspiration in patients with mediastinal masses and lymph nodes. Turk. J.
Gastroenterol. 22 (5), 472–478.
Vargha-Butler, E.I., et al., 2001. Wettability of biodegradable surfaces. Colloid Polym. Sci.
279 (12), 1160–1168.
Voigt, M., Koerber, M., Bodmeier, R., 2012. Improved physical stability and injectability
of non-aqueous in situ PLGA microparticle forming emulsions. Int. J. Pharm. 434
(1–2), 251–256.
Whitaker, M.A., et al., 2011. Particle size and shape eﬀects in medical syringe needles:
experiments and simulations for polymer microparticle injection. J. Mater. Sci.
Mater. Med. 22 (8), 1975–1983.
Xu, D., et al., 1995. Studies of protective properties of pluronic and other agents on the
hybridoma cell culture. Chin. J. Biotechnol. 11 (2), 101–107.
O. Qutachi et al. International Journal of Pharmaceutics 546 (2018) 272–278
278
